Literature DB >> 23288416

Long-term use of aspirin and age-related macular degeneration.

Barbara E K Klein1, Kerri P Howard, Ronald E Gangnon, Jennifer O Dreyer, Kristine E Lee, Ronald Klein.   

Abstract

CONTEXT: Aspirin is widely used for relief of pain and for cardioprotective effects. Its use is of concern to ophthalmologists when ocular surgery is being considered and also in the presence of age-related macular degeneration (AMD).
OBJECTIVE: To examine the association of regular aspirin use with incidence of AMD. DESIGN, SETTING, AND PARTICIPANTS: The Beaver Dam Eye Study, a longitudinal population-based study of age-related eye diseases conducted in Wisconsin. Examinations were performed every 5 years over a 20-year period (1988-1990 through 2008-2010). Study participants (N = 4926) were aged 43 to 86 years at the baseline examination. At subsequent examinations, participants were asked if they had regularly used aspirin at least twice a week for more than 3 months. MAIN OUTCOME MEASURE: Incidence of early AMD, late AMD, and 2 subtypes of late AMD (neovascular AMD and pure geographic atrophy), assessed in retinal photographs according to the Wisconsin Age-Related Maculopathy Grading System.
RESULTS: The mean duration of follow-up was 14.8 years. There were 512 incident cases of early AMD (of 6243 person-visits at risk) and 117 incident cases of late AMD (of 8621 person-visits at risk) over the course of the study. Regular aspirin use 10 years prior to retinal examination was associated with late AMD (hazard ratio [HR], 1.63 [95% CI, 1.01-2.63]; P = .05), with estimated incidence of 1.76% (95% CI, 1.17%-2.64%) in regular users and 1.03% (95% CI, 0.70%-1.51%) in nonusers. For subtypes of late AMD, regular aspirin use 10 years prior to retinal examination was significantly associated with neovascular AMD (HR, 2.20 [95% CI, 1.20-4.15]; P = .01) but not pure geographic atrophy (HR, 0.66 [95% CI, 0.25-1.95]; P = .45). Aspirin use 5 years (HR, 0.86 [95% CI, 0.71-1.05]; P = .13) or 10 years (HR, 0.86 [95% CI, 0.65-1.13]; P = .28) prior to retinal examination was not associated with incident early AMD.
CONCLUSIONS: Among an adult cohort, aspirin use 5 years prior to observed incidence was not associated with incident early or late AMD. However, regular aspirin use 10 years prior was associated with a small but statistically significant increase in the risk of incident late and neovascular AMD.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23288416      PMCID: PMC3630794          DOI: 10.1001/jama.2012.65406

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  19 in total

1.  Low-dose aspirin and medical record-confirmed age-related macular degeneration in a randomized trial of women.

Authors:  William G Christen; Robert J Glynn; Emily Y Chew; Julie E Buring
Journal:  Ophthalmology       Date:  2009-10-07       Impact factor: 12.079

2.  Changes in visual acuity in a population over a 15-year period: the Beaver Dam Eye Study.

Authors:  Ronald Klein; Barbara E K Klein; Kristine E Lee; Karen J Cruickshanks; Ronald E Gangnon
Journal:  Am J Ophthalmol       Date:  2006-10       Impact factor: 5.258

3.  Associations between aspirin use and aging macula disorder: the European Eye Study.

Authors:  Paulus T V M de Jong; Usha Chakravarthy; Mati Rahu; Johan Seland; Gisele Soubrane; Fotis Topouzis; Johannes R Vingerling; Jesus Vioque; Ian Young; Astrid E Fletcher
Journal:  Ophthalmology       Date:  2011-09-13       Impact factor: 12.079

4.  Changes in visual acuity in a population. The Beaver Dam Eye Study.

Authors:  R Klein; B E Klein; K E Lee
Journal:  Ophthalmology       Date:  1996-08       Impact factor: 12.079

5.  Release of angiogenesis regulatory proteins from platelet alpha granules: modulation of physiologic and pathologic angiogenesis.

Authors:  Elisabeth M Battinelli; Beth A Markens; Joseph E Italiano
Journal:  Blood       Date:  2011-06-16       Impact factor: 22.113

6.  Prevalence of age-related maculopathy. The Beaver Dam Eye Study.

Authors:  R Klein; B E Klein; K L Linton
Journal:  Ophthalmology       Date:  1992-06       Impact factor: 12.079

7.  Serum cystatin C and the incidence of type 2 diabetes mellitus.

Authors:  K Sahakyan; K E Lee; A Shankar; R Klein
Journal:  Diabetologia       Date:  2011-03-05       Impact factor: 10.122

8.  The five-year incidence and progression of age-related maculopathy: the Beaver Dam Eye Study.

Authors:  R Klein; B E Klein; S C Jensen; S M Meuer
Journal:  Ophthalmology       Date:  1997-01       Impact factor: 12.079

9.  Influence of anti-inflammatory and vasoactive drugs on microcirculation and angiogenesis after burn in mice.

Authors:  O Goertz; A Ring; B Buschhaus; T Hirsch; A Daigeler; L Steinstraesser; H-U Steinau; S Langer
Journal:  Burns       Date:  2011-02-22       Impact factor: 2.744

10.  Epidemiology of the association between anticoagulants and intraocular hemorrhage in patients with neovascular age-related macular degeneration.

Authors:  Daniel F Kiernan; Seenu M Hariprasad; Irene M Rusu; Sahil V Mehta; William F Mieler; Rama D Jager
Journal:  Retina       Date:  2010 Nov-Dec       Impact factor: 4.256

View more
  15 in total

1.  [Ophthalmological aspects of the Gutenberg Health Study (GHS): an interdisciplinary prospective population-based cohort study].

Authors:  A Mirshahi; K A Ponto; R Höhn; P S Wild; N Pfeiffer
Journal:  Ophthalmologe       Date:  2013-03       Impact factor: 1.059

2.  The Association of Aspirin Use with Age-Related Macular Degeneration Progression in the Age-Related Eye Disease Studies: Age-Related Eye Disease Study 2 Report No. 20.

Authors:  Tiarnan D Keenan; Henry E Wiley; Elvira Agrón; Mary E Aronow; William G Christen; Traci E Clemons; Emily Y Chew
Journal:  Ophthalmology       Date:  2019-06-26       Impact factor: 12.079

3.  Age-related macular degeneration in patients with uveitis.

Authors:  Austin R Fox; Emily Y Chew; Catherine Meyerle; Susan Vitale; Frederick L Ferris; Robert B Nussenblatt; H Nida Sen
Journal:  Br J Ophthalmol       Date:  2016-05-06       Impact factor: 4.638

4.  Cytochrome P450-generated metabolites derived from ω-3 fatty acids attenuate neovascularization.

Authors:  Ryoji Yanai; Lama Mulki; Eiichi Hasegawa; Kimio Takeuchi; Harry Sweigard; Jun Suzuki; Philipp Gaissert; Demetrios G Vavvas; Koh-Hei Sonoda; Michael Rothe; Wolf-Hagen Schunck; Joan W Miller; Kip M Connor
Journal:  Proc Natl Acad Sci U S A       Date:  2014-06-16       Impact factor: 11.205

5.  Thyroid function: a new road to understanding age-related macular degeneration?

Authors:  Till Ittermann; Clemens Jürgens
Journal:  BMC Med       Date:  2015-04-23       Impact factor: 8.775

Review 6.  Aspirin and age related macular degeneration; the possible relationship.

Authors:  Yan Wu; Wei Zhu; Yan-Hong Li; Jing Yu
Journal:  Med Hypothesis Discov Innov Ophthalmol       Date:  2013

7.  Cognitive Impairment and Age-Related Vision Disorders: Their Possible Relationship and the Evaluation of the Use of Aspirin and Statins in a 65 Years-and-Over Sardinian Population.

Authors:  Antonella Mandas; Rosa Maria Mereu; Olga Catte; Antonio Saba; Luca Serchisu; Diego Costaggiu; Enrico Peiretti; Giulia Caminiti; Michela Vinci; Maura Casu; Stefania Piludu; Maurizio Fossarello; Paolo Emilio Manconi; Sandra Dessí
Journal:  Front Aging Neurosci       Date:  2014-11-07       Impact factor: 5.750

Review 8.  Does the use of acetylsalicylic acid have an influence on our vision?

Authors:  Katarzyna Michalska-Małecka; Agnieszka Regucka; Dorota Śpiewak; Magdalena Sosnowska-Pońska; Alfred Niewiem
Journal:  Clin Interv Aging       Date:  2016-11-03       Impact factor: 4.458

9.  Aspirin use and risk of age-related macular degeneration: a meta-analysis.

Authors:  Wei Zhu; Yan Wu; Ding Xu; Yan-Hong Li; Ba Jun; Xiao-Long Zhang; Fang Wang; Jing Yu
Journal:  PLoS One       Date:  2013-03-14       Impact factor: 3.240

10.  Four-year incidence of diabetic retinopathy in a Spanish cohort: the MADIABETES study.

Authors:  Miguel Á Salinero-Fort; Francisco Javier San Andrés-Rebollo; Carmen de Burgos-Lunar; Francisco Jesús Arrieta-Blanco; Paloma Gómez-Campelo
Journal:  PLoS One       Date:  2013-10-17       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.